Evidence map›Paper›PMID 21659362›Full record

ArticleHaematologica2011

Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles.

Heike Horn, Christopher Schmelter, Ellen Leich, Itziar Salaverria, Tiemo Katzenberger, M Michaela Ott, Jörg Kalla, Monica Romero, Reiner Siebert, Andreas Rosenwald and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04508647 (Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response), which is not on this map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04508647 phase2completednot on this mapstarted 2020, after this paper: background citation

Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response

TypeinterventionalSponsorUniversity of Colorado, DenverRan2020 to 2022Enrolled4ConditionsMarginal Zone Lymphoma, Follicular LymphomaArmsUblituximab, Umbralisib
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 167 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Advancements in the Management of Follicular Lymphoma: A Comprehensive ReviewTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024
    Review
  10. B-cell non-Hodgkin lymphomas.Lancet (London, England) · 2024
    Review
  11. Article
  12. Review
  13. The pathobiology of follicular lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2023
    Article
  14. Article
  15. Article
  16. T-cell phenotype including CD57Blood cancer journal · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Heike HornDepartement of Clinical Pathology, Robert-Bosch-Hospital, Stuttgart, Germany.
Christopher Schmelter
Ellen Leich
Itziar Salaverria
Tiemo Katzenberger
M Michaela Ott
Jörg Kalla
Monica Romero
Reiner Siebert
Andreas Rosenwald
German Ott
University of Würzburg · DEUniversity Hospital Schleswig-Holstein · DECaritas-Krankenhaus Bad Mergentheim · DEDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DEKlinikum Aschaffenburg · DERobert Bosch Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccording to the current World Health Organization Classification of Lymphoid Tumours, follicular lymphoma is subclassified into three grades according to the number of centroblasts. Follicular lymphoma grade 3 can be further divided into types A and B. Almost all available genetic data on grade 3B follicular lymphomas have been generated from tumors with an additional diffuse large B-cell lymphoma component. The purely follicular type of follicular lymphoma grade 3B is a rare neoplasm. DESIGN AND

methodsWe performed a detailed immunohistochemical (CD10, IRF4/MUM1, BCL2, Ig light chains) and genetic (translocations of BCL2, BCL6, MYC, IRF4) characterization of the largest series of purely follicular cases of grade 3B follicular lymphoma available to date, comprising 23 tumor samples. We also included 25 typical grade 1 or 2 follicular lymphomas, 9 follicular lymphomas with large centrocytes and/or high proliferation indices (FL/LCC), 12 cases of follicular lymphoma grade 3A, 16 cases of diffuse large B-cell lymphoma/follicular lymphoma grade 3B and 15 follicular lymphomas in which a straightforward distinction between grades 3A and 3B was not possible.

resultsTranslocations affecting BCL2 and BCL6 genes are rare in grade 3B follicular lymphomas (2/23, 9% and 4/23, 17%) when compared with grade 1 or 2 follicular lymphomas (22/25, 88%, P<0.001 and 0/25, P<0.05), FL/LCC (7/9, 78%, P<0.001 and 2/9, 22%), grade 3A follicular lymphomas (7/12, 58%, P<0.01 and 2/12, 17%), unclassified grade 3 follicular lymphomas (6/15, 40% and 2/15, 13%) and diffuse large B-cell lymphoma/follicular lymphoma grade 3B (2/16, 13% and 8/16, 50%, P<0.05). MYC translocations were detected occasionally in FL/LCC, follicular lymphoma grade 3B, and diffuse large B-cell lymphoma/follicular lymphoma grade 3B (13%-22%), but not in grade 1, 2 or 3A follicular lymphomas (P<0.05 when compared with follicular lymphoma grade 3B). Both follicular lymphoma grade 3B and diffuse large B-cell lymphoma/follicular lymphoma grade 3B were enriched in samples with a CD10(-)IRF4/MUM1(+) immunophenotype (8/19, 42% and 7/16, 44%), with the vast majority of them lacking BCL2 translocations. In contrast, 42/46 grade 1 or 2 follicular lymphomas, FL/LCC and grade 3A follicular lymphomas were CD10(+) (91%) while 0/46 expressed IRF4/MUM1. None of the tumor samples tested with increased IRF4/MUM1-expression harbored a translocation of the IRF4 gene locus.

conclusionsOur results show that grade 3B follicular lymphomas form a distinct category of follicular lymphomas with infrequent BCL2 and BCL6 translocations, while grades 1, 2 and 3A follicular lymphomas and FL/LCC display homogeneous features with frequent BCL2 translocations and a CD10(+)IRF4/MUM1(-) immunophenotype.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChromosome BreakageCytogenetic AnalysisGene Expression Regulation, NeoplasticHumansImmunohistochemistryImmunophenotypingLymphoma, FollicularMiddle AgedNeoplasm GradingProto-Oncogene ProteinsTranslocation, GeneticProto-Oncogene Proteins

Identifiers

PMID21659362
PMCPMC3166103
OpenAlexW2140867490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.